{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T03:20:34Z","timestamp":1786591234658,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Sponsored by Fujian Provincial Health Technology Project","award":["No. 2023QNA022"],"award-info":[{"award-number":["No. 2023QNA022"]}]},{"name":"Supported by Fujian Provincial Natural Science Foundation of China","award":["No. 2023J01673"],"award-info":[{"award-number":["No. 2023J01673"]}]},{"name":"Startup Fund for Scientific Research, Fujian Medical University","award":["No. 2022QH1174"],"award-info":[{"award-number":["No. 2022QH1174"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s10620-025-09402-3","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T11:56:03Z","timestamp":1758887763000},"page":"948-960","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["NCAPD2 Modulates MHC-I Antigen Presentation via the PI3K\/AKT Axis to Drive Metastatic Progression in Gastric Cancer"],"prefix":"10.1007","volume":"71","author":[{"given":"Qiong","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"9402_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74:229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834 (from NLM Medline).","journal-title":"CA Cancer J Clin"},{"key":"9402_CR2","doi-asserted-by":"publisher","first-page":"386","DOI":"10.21037\/jgo.2020.03.01","volume":"11","author":"Z Feng","year":"2020","unstructured":"Feng Z, Qiao R, Ren Z, et al. Could CTSK and COL4A2 be specific biomarkers of poor prognosis for patients with gastric cancer in Asia? A microarray analysis based on regional population. J Gastrointest Oncol 2020;11:386\u2013401. https:\/\/doi.org\/10.21037\/jgo.2020.03.01 (from NLM PubMed-not-MEDLINE).","journal-title":"J Gastrointest Oncol"},{"key":"9402_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13045-023-01451-3","volume":"16","author":"WL Guan","year":"2023","unstructured":"Guan WL, He Y, Xu RH. Gastric cancer treatment: recent progress and future perspectives. J Hematol Oncol 2023;16:57. https:\/\/doi.org\/10.1186\/s13045-023-01451-3 (from NLM Medline).","journal-title":"J Hematol Oncol"},{"key":"9402_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104197","volume":"198","author":"G Wang","year":"2024","unstructured":"Wang G, Huang Y, Zhou L, et al. Immunotherapy and targeted therapy as first-line treatment for advanced gastric cancer. Crit Rev Oncol Hematol 2024;198:104197. https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104197 (from NLM Medline).","journal-title":"Crit Rev Oncol Hematol"},{"key":"9402_CR5","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3748\/wjg.v30.i4.286","volume":"30","author":"G Christodoulidis","year":"2024","unstructured":"Christodoulidis G, Koumarelas KE, Kouliou MN. Revolutionizing gastric cancer treatment: the potential of immunotherapy. World J Gastroenterol 2024;30:286\u2013289. https:\/\/doi.org\/10.3748\/wjg.v30.i4.286 (from NLM Medline).","journal-title":"World J Gastroenterol"},{"key":"9402_CR6","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.1007\/s12033-023-00896-8","volume":"66","author":"B Tang","year":"2024","unstructured":"Tang B, Bi L, Xu Y, Cao L, Li X. N(6)-methyladenosine (m(6)A) reader IGF2BP1 accelerates gastric cancer development and immune escape by targeting PD-L1. Mol Biotechnol 2024;66:2850\u20132859. https:\/\/doi.org\/10.1007\/s12033-023-00896-8 (from NLM Medline).","journal-title":"Mol Biotechnol"},{"key":"9402_CR7","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1158\/2326-6066.CIR-22-0218","volume":"10","author":"T Shi","year":"2022","unstructured":"Shi T, Zhang Y, Wang Y, et al. DKK1 promotes tumor immune evasion and impedes anti-PD-1 treatment by inducing immunosuppressive macrophages in gastric cancer. Cancer Immunol Res 2022;10:1506\u20131524. https:\/\/doi.org\/10.1158\/2326-6066.CIR-22-0218 (from NLM Medline).","journal-title":"Cancer Immunol Res"},{"key":"9402_CR8","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1600-065x.1989.tb00022.x","volume":"109","author":"JE de Vries","year":"1989","unstructured":"de Vries JE, Yssel H, Spits H. Interplay between the TCR\/CD3 complex and CD4 or CD8 in the activation of cytotoxic T lymphocytes. Immunol Rev 1989;109:119\u2013141. https:\/\/doi.org\/10.1111\/j.1600-065x.1989.tb00022.x (from NLM Medline).","journal-title":"Immunol Rev"},{"key":"9402_CR9","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.molimm.2012.05.004","volume":"52","author":"J Huang","year":"2012","unstructured":"Huang J, Meyer C, Zhu C. T cell antigen recognition at the cell membrane. Mol Immunol 2012;52:155\u2013164. https:\/\/doi.org\/10.1016\/j.molimm.2012.05.004 (from NLM Medline).","journal-title":"Mol Immunol"},{"key":"9402_CR10","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/s41577-022-00707-2","volume":"22","author":"N Pishesha","year":"2022","unstructured":"Pishesha N, Harmand TJ, Ploegh HL. A guide to antigen processing and presentation. Nat Rev Immunol 2022;22:751\u2013764. https:\/\/doi.org\/10.1038\/s41577-022-00707-2 (from NLM Medline).","journal-title":"Nat Rev Immunol"},{"key":"9402_CR11","doi-asserted-by":"publisher","DOI":"10.1172\/JCI153167","author":"J Ren","year":"2022","unstructured":"Ren J, Li N, Pei S, et al. Histone methyltransferase WHSC1 loss dampens MHC-I antigen presentation pathway to impair IFN-gamma-stimulated antitumor immunity. J Clin Investig. 2022. https:\/\/doi.org\/10.1172\/JCI153167 (from NLM Medline).","journal-title":"J Clin Investig"},{"key":"9402_CR12","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.cell.2017.05.035","volume":"169","author":"C Zheng","year":"2017","unstructured":"Zheng C, Zheng L, Yoo JK, et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell 2017;169:1342-1356.e1316. https:\/\/doi.org\/10.1016\/j.cell.2017.05.035 (from NLM Medline).","journal-title":"Cell"},{"key":"9402_CR13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.canlet.2021.06.029","volume":"520","author":"Z Jing","year":"2021","unstructured":"Jing Z, He X, Jia Z, Sa Y, Yang B, Liu P. NCAPD2 inhibits autophagy by regulating Ca(2+)\/CAMKK2\/AMPK\/mTORC1 pathway and PARP-1\/SIRT1 axis to promote colorectal cancer. Cancer Lett 2021;520:26\u201337. https:\/\/doi.org\/10.1016\/j.canlet.2021.06.029 (from NLM Medline).","journal-title":"Cancer Lett"},{"key":"9402_CR14","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/cas.15347","volume":"114","author":"J He","year":"2023","unstructured":"He J, Gao R, Yang J, et al. NCAPD2 promotes breast cancer progression through E2F1 transcriptional regulation of CDK1. Cancer Sci 2023;114:896\u2013907. https:\/\/doi.org\/10.1111\/cas.15347 (from NLM Medline).","journal-title":"Cancer Sci"},{"key":"9402_CR15","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2024.5408","author":"JX Gu","year":"2024","unstructured":"Gu JX, Huang K, Zhao WL, et al. NCAPD2 augments the tumorigenesis and progression of human liver cancer via the PI3K-Akt-mTOR signaling pathway. Int J Mol Med. 2024. https:\/\/doi.org\/10.3892\/ijmm.2024.5408 (from NLM Medline).","journal-title":"Int J Mol Med"},{"key":"9402_CR16","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s41021-023-00291-4","volume":"46","author":"L Feng","year":"2024","unstructured":"Feng L, Yang Y, Lin Z, Cui M, Jin A, Cui A. NCPAD2 is a favorable predictor of prognostic and immunotherapeutic biomarker for multiple cancer types including lung cancer. Genes Environ 2024;46:2. https:\/\/doi.org\/10.1186\/s41021-023-00291-4 (from NLM PubMed-not-Medline).","journal-title":"Genes Environ"},{"key":"9402_CR17","doi-asserted-by":"publisher","first-page":"7237","DOI":"10.18632\/aging.204904","volume":"15","author":"X Dong","year":"2023","unstructured":"Dong X, Liu T, Li Z, Zhai Y. Non-SMC condensin I complex subunit D2 (NCAPD2) reveals its prognostic and immunologic features in human cancers. Aging (Albany NY) 2023;15:7237\u20137257. https:\/\/doi.org\/10.18632\/aging.204904 (from NLM Medline).","journal-title":"Aging (Albany NY)"},{"key":"9402_CR18","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3892\/ol.2020.11612","volume":"20","author":"Q Luo","year":"2020","unstructured":"Luo Q, Zhang S, Zhang D, Yuan F, Chen X, Yang S. Expression of ASAP1 and FAK in gastric cancer and its clinicopathological significance. Oncol Lett 2020;20:974\u2013980. https:\/\/doi.org\/10.3892\/ol.2020.11612 (from NLM PubMed-not-Medline).","journal-title":"Oncol Lett"},{"key":"9402_CR19","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3892\/or.2020.7890","volume":"45","author":"Z Guo","year":"2021","unstructured":"Guo Z, Zhang X, Zhu H, et al. TELO2 induced progression of colorectal cancer by binding with RICTOR through mTORC2. Oncol Rep 2021;45:523\u2013534. https:\/\/doi.org\/10.3892\/or.2020.7890 (from NLM Medline).","journal-title":"Oncol Rep"},{"key":"9402_CR20","first-page":"280","volume":"7","author":"T Hou","year":"2014","unstructured":"Hou T, Yang C, Tong C, Zhang H, Xiao J, Li J. Overexpression of ASAP1 is associated with poor prognosis in epithelial ovarian cancer. Int J Clin Exp Pathol 2014;7:280\u2013287 (from NLM Medline).","journal-title":"Int J Clin Exp Pathol"},{"key":"9402_CR21","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.18457","volume":"4","author":"MCS Wong","year":"2021","unstructured":"Wong MCS, Huang J, Chan PSF, et al. Global incidence and mortality of gastric cancer, 1980\u20132018. JAMA Netw Open 2021;4:e2118457. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.18457 (from NLM Medline).","journal-title":"JAMA Netw Open"},{"key":"9402_CR22","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.3389\/fimmu.2020.01402","volume":"11","author":"S DeCordova","year":"2020","unstructured":"DeCordova S, Shastri A, Tsolaki AG, et al. Molecular heterogeneity and immunosuppressive microenvironment in glioblastoma. Front Immunol 2020;11:1402. https:\/\/doi.org\/10.3389\/fimmu.2020.01402 (from NLM Medline).","journal-title":"Front Immunol"},{"key":"9402_CR23","doi-asserted-by":"publisher","first-page":"9303632","DOI":"10.1155\/2023\/9303632","volume":"2023","author":"B Zhai","year":"2023","unstructured":"Zhai B, Wu J, Li T. Fibroblast growth factor 11 enables tumor cell immune escape by promoting T cell exhaustion and predicts poor prognosis in patients with lung adenocarcinoma. J Oncol 2023;2023:9303632. https:\/\/doi.org\/10.1155\/2023\/9303632 (from NLM PubMed-not-Medline).","journal-title":"J Oncol"},{"key":"9402_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25115880","author":"T Matsuoka","year":"2024","unstructured":"Matsuoka T, Yashiro M. Bioinformatics analysis and validation of potential markers associated with prediction and prognosis of gastric cancer. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25115880 (from NLM Medline).","journal-title":"Int J Mol Sci"},{"key":"9402_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004874","author":"G Deng","year":"2022","unstructured":"Deng G, Zhou L, Wang B, et al. Targeting cathepsin B by cycloastragenol enhances antitumor immunity of CD8 T cells via inhibiting MHC-I degradation. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2022-004874 (from NLM Medline).","journal-title":"J Immunother Cancer"},{"key":"9402_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202207067","volume":"10","author":"J Li","year":"2023","unstructured":"Li J, Wang K, Yang C, et al. Tumor-associated macrophage-derived exosomal LINC01232 induces the immune escape in glioma by decreasing surface MHC-I expression. Adv Sci (Weinh) 2023;10:e2207067. https:\/\/doi.org\/10.1002\/advs.202207067 (from NLM Medline).","journal-title":"Adv Sci (Weinh)"},{"key":"9402_CR27","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1158\/2326-6066.CIR-22-0815","volume":"11","author":"K Kawase","year":"2023","unstructured":"Kawase K, Kawashima S, Nagasaki J, et al. High expression of MHC Class I overcomes cancer immunotherapy resistance due to IFNgamma signaling pathway defects. Cancer Immunol Res 2023;11:895\u2013908. https:\/\/doi.org\/10.1158\/2326-6066.CIR-22-0815 (from NLM Medline).","journal-title":"Cancer Immunol Res"},{"key":"9402_CR28","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1038\/s12276-023-01062-5","volume":"55","author":"X Ren","year":"2023","unstructured":"Ren X, Feng C, Wang Y, et al. SLC39A10 promotes malignant phenotypes of gastric cancer cells by activating the CK2-mediated MAPK\/ERK and PI3K\/AKT pathways. Exp Mol Med 2023;55:1757\u20131769. https:\/\/doi.org\/10.1038\/s12276-023-01062-5 (from NLM Medline).","journal-title":"Exp Mol Med"},{"key":"9402_CR29","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12916-022-02327-y","volume":"20","author":"Z Wang","year":"2022","unstructured":"Wang Z, Wang X, Xu Y, et al. Mutations of PI3K-AKT-mTOR pathway as predictors for immune cell infiltration and immunotherapy efficacy in dMMR\/MSI-H gastric adenocarcinoma. BMC Med 2022;20:133. https:\/\/doi.org\/10.1186\/s12916-022-02327-y (from NLM Medline).","journal-title":"BMC Med"},{"key":"9402_CR30","doi-asserted-by":"publisher","first-page":"6863240","DOI":"10.1155\/2022\/6863240","volume":"2022","author":"Q Wang","year":"2022","unstructured":"Wang Q, Cao T, Zhang X, et al. ATXN2-mediated PI3K\/AKT activation confers gastric cancer chemoresistance and attenuates CD8(+) T cell cytotoxicity. J Immunol Res 2022;2022:6863240. https:\/\/doi.org\/10.1155\/2022\/6863240 (from NLM Medline).","journal-title":"J Immunol Res"},{"key":"9402_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12571","volume":"52","author":"R Zhao","year":"2019","unstructured":"Zhao R, Song Y, Wang Y, et al. PD-1\/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K\/Akt\/mTOR signalling pathway. Cell Prolif 2019;52:e12571. https:\/\/doi.org\/10.1111\/cpr.12571 (from NLM Medline).","journal-title":"Cell Prolif"},{"key":"9402_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202305922","volume":"11","author":"X Zheng","year":"2024","unstructured":"Zheng X, Chen J, Deng M, et al. G3BP1 and SLU7 jointly promote immune evasion by downregulating MHC-I via PI3K\/Akt activation in bladder cancer. Adv Sci (Weinh) 2024;11:e2305922. https:\/\/doi.org\/10.1002\/advs.202305922 (from NLM Medline).","journal-title":"Adv Sci (Weinh)"},{"key":"9402_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.774323","volume":"12","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Xie T, Mo G, Zhang Z, Lin L, Zhang X. ACSL1 inhibits ALV-J replication by IFN-I signaling and PI3K\/Akt pathway. Front Immunol 2021;12:774323. https:\/\/doi.org\/10.3389\/fimmu.2021.774323 (from NLM Medline).","journal-title":"Front Immunol"},{"key":"9402_CR34","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1016\/j.cell.2024.04.025","volume":"187","author":"MB Maxwell","year":"2024","unstructured":"Maxwell MB, Hom-Tedla MS, Yi J, et al. ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity. Cell 2024;187:3390-3408.e3319. https:\/\/doi.org\/10.1016\/j.cell.2024.04.025 (from NLM Medline).","journal-title":"Cell"},{"key":"9402_CR35","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.immuni.2021.10.020","volume":"55","author":"E Duong","year":"2022","unstructured":"Duong E, Fessenden TB, Lutz E, et al. Type I interferon activates MHC class I-dressed CD11b(+) conventional dendritic cells to promote protective anti-tumor CD8(+) T cell immunity. Immunity 2022;55:308-323.e309. https:\/\/doi.org\/10.1016\/j.immuni.2021.10.020 (from NLM Medline).","journal-title":"Immunity"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09402-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-025-09402-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09402-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:10:51Z","timestamp":1773292251000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-025-09402-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["9402"],"URL":"https:\/\/doi.org\/10.1007\/s10620-025-09402-3","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"11 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of Fujian Medical University Union Hospital, Approval Number 2023WSJK001.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}